Biogen Inc. $BIIB Stock Holdings Reduced by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. reduced its position in Biogen Inc. (NASDAQ:BIIB) by 12.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,300 shares of the biotechnology company’s stock after selling 3,300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Biogen were worth $4,101,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in BIIB. Advisory Services Network LLC grew its stake in shares of Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 68 shares in the last quarter. CVA Family Office LLC raised its position in Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 71 shares in the last quarter. Davis Investment Partners LLC lifted its stake in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in Biogen by 22.5% in the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 76 shares during the last quarter. Finally, CX Institutional grew its position in Biogen by 6.1% in the third quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 83 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on BIIB shares. Guggenheim increased their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Truist Financial upped their price objective on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday, February 9th. Barclays started coverage on shares of Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price on the stock. Citigroup raised their target price on Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a report on Monday, February 9th. Finally, TD Cowen boosted their price target on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and a consensus target price of $208.31.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Acquisition adds approved immunology drugs and revenue: Biogen agreed to acquire Apellis for $5.6B, bringing Syfovre and Empaveli into Biogen’s portfolio and accelerating its push into immunology and rare disease — a clear strategic fit that should boost near-term revenue and pipeline depth. Article Title
• Positive Sentiment: Analysts lift targets and maintain conviction: Multiple firms raised price targets and ratings (Oppenheimer to $275/outperform; Canaccord to $245/buy; HC Wainwright to $237/buy), signaling institutional support for the M&A rationale and longer‑term upside. Article Title Article Title
• Neutral Sentiment: Apellis shares surged on the deal — APLS jumped dramatically (reflecting takeover premium), which is expected after an agreed cash offer but does not directly change Biogen’s near-term cash obligations. Article Title
• Neutral Sentiment: CFO frames deal as debt-neutral/strategic: Biogen’s CFO said combined cash flows and balance-sheet management free capacity for further deals, positioning the company to pursue more early-stage acquisitions. This is strategic context rather than an immediate earnings boost. Article Title
• Neutral Sentiment: Mixed analyst stance: Wedbush raised its price target modestly to $191 but kept a neutral rating, underscoring some caution among analysts despite other upgrades. Article Title
• Negative Sentiment: Investor selling on cash outlay and short-term dilution/near-term risk: Some market participants sold BIIB after the deal announcement, viewing the $5.6B cash use as a near-term headwind despite strategic merits — this is likely the proximate cause of today’s downside. Article Title
• Negative Sentiment: Legal scrutiny on the sale: A plaintiff firm announced an investigation into the adequacy of the Apellis sale price/process, creating a small but nonzero regulatory/legal overhang that could delay or complicate closing. Article Title

Biogen Price Performance

Shares of Biogen stock opened at $177.34 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a fifty day simple moving average of $186.48 and a 200-day simple moving average of $171.11. The stock has a market capitalization of $26.03 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 1.46 and a beta of 0.16. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same period last year, the business posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.